<DOC>
	<DOCNO>NCT02722668</DOCNO>
	<brief_summary>This phase II trial use non-myeloablative cyclophosphamide/ fludarabine/total body irradiation ( TBI ) preparative regimen modification base factor include diagnosis , disease status , prior treatment . Single double unit select accord current University Minnesota umbilical cord blood graft selection algorithm .</brief_summary>
	<brief_title>UCB Transplant Hematological Diseases Using Non Myeloablative Prep</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Age , Performance Status , Graft Criteria &lt; 70 year age match 5/6 6/6 sibling donor patient ≥ 70 ≤ 75 year age may eligible CoMorbidity score ≤ 2 refer appendix II Karnofsky score ≥ 70 % ( ≥ 16 year ) Lansky score ≥ 50 ( &lt; 16 year ) UCB graft select accord current University Minnesota umbilical cord blood graft selection algorithm Eligible Diseases All disease list advanced hematologic malignancy curable conventional chemotherapy . Responses conventional treatment range zero 30 % typically short live . Acute Leukemias : Must remission morphology ( &lt; 5 % blast ) . Note cytogenetic relapse persistent disease without morphologic relapse acceptable . Also small percentage blast equivocal marrow regeneration vs. early relapse acceptable provide associate cytogenetic marker consistent relapse . Acute myeloid leukemia : high risk first complete remission ( CR1 ) ( evidence precede myelodysplastic syndrome [ MDS ] , high risk cytogenetics associated MDS complex karyotype , &gt; 2 cycle obtain CR erythroblastic megakaryocytic leukemia , FLT3 ITD + ) ; second great CR . Acute lymphoblastic leukemia/lymphoma : high risk CR1 evidence high risk cytogenetics ( e.g . ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , mixedlineage leukemia ( MLL ) rearrangement , hypodiploidy IKZF1 ) , &gt; 1 cycle obtain complete remission ( CR ) evidence minimal residual disease ( MRD ) . Patients second great CR also eligible . Burkitt 's lymphoma CR2 subsequent CR Natural killer cell malignancy Chronic myelogenous leukemia ( CML ) : type except refractory blast crisis . Chronic phase patient must fail intolerant least two tyrosine kinase inhibitor . Myelodysplastic syndrome require transplant define : IPSS INT2 High Risk ; RIPSS High Very High ; WHO classification : RAEB1 , RAEB2 ; Severe Cytopenias : ANC &lt; 0.8 , PRBC platelets require transfusion ; Higher risk cytogenetics base IPSS RIPSS definition ; therapyrelated MDS . Blasts must &lt; 5 % representative bone marrow aspirate morphology . Largecell lymphoma , Hodgkin lymphoma multiple myeloma chemotherapy sensitive disease ineligible autologous transplant . Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone Bcell lymphoma , follicular lymphoma progress within 12 month achieve partial complete remission . Patients remission last &gt; 12 month , eligible least two prior therapy . Patients bulky disease consider debulking chemotherapy transplant . Patients refractory disease eligible , unless bulky disease estimate tumor double time le one month . Lymphoplasmacytic lymphoma , mantlecell lymphoma , prolymphocytic leukemia eligible initial therapy chemotherapy sensitive . Bone marrow failure syndrome , except Fanconi anemia Myeloproliferative syndrome Additional Criteria Bulky Disease ( lymphoma ) If stable disease best response , large residual nodal mass must &lt; 5 cm ( approximately ) If response previous therapy , large residual mass must represent 50 % reduction &lt; 7.5 cm ( approximately ) Organ Function Criteria Adequate organ function define : Cardiac : Absence decompensated congestive heart failure , uncontrolled arrhythmia leave ventricular ejection fraction &gt; 35 % . Pulmonary : DLCOcorr ≥ 40 % predict , absence O2 requirement . For child able cooperate PFTs , pulse oximetry without exercise attempt . If neither test obtain clearly state physician 's note . Liver : AST ALT &lt; 5 x upper limit normal bilirubin &lt; 3 x upper limit normal Renal : Creatinine ≤ 2.0 mg/dl ( adult ) estimate glomerular filtration rate ( GFR ) ≥ 40 mL/min ( pediatrics ) . Adults creatinine &gt; 1.2 mg/dl history renal dysfunction must estimate glomerular filtration rate ( GFR ) &gt; 40 mL/min . Women childbearing potential male partner childbearing potential must agree use adequate birth control study treatment . Voluntary write consent ( adult parent/guardian presentation minor information sheet , appropriate ) Pregnant breast feeding . The agent use study include Pregnancy Category D : know cause harm fetus . Females childbearing potential must negative pregnancy test prior start therapy . Untreated active infection Active HIV infection know HIV positive serology Less 3 month since prior myeloablative transplant ( applicable ) Evidence progressive disease image modality biopsy persistent PET activity , though possibly relate lymphoma , exclusion criterion absence CT change indicate progression . CML blast crisis Large cell lymphoma , mantle cell lymphoma Hodgkin disease progress salvage therapy . Active central nervous system malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
</DOC>